GlassScriptPhysician profile
Rafat Choudhry
NPI 1467538835
$7,075.12
in general payments reported to CMS, 2019-2025
47 companies · $675 in 2025
The $675 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,224 · 2020: $722 · 2021: $821 · 2022: $1,226 · 2023: $1,523 · 2024: $884 · 2025: $675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,082.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,082.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,031.92 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $1,005.05 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $541.04 | 2019-2025 | Relistor, Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $509.34 | 2019-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $491.14 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $466.33 | 2019-2023 | |
| Lilly USA, LLC | $347.81 | 2019-2025 | Mounjaro, Trulicity, Jardiance |
| Glaxosmithkline, LLC. | $291.93 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Smith+Nephew, INC. | $271.62 | 2019-2025 | Collagenase Santyl, Stravix, Pico 14 |
| Pfizer INC. | $224.72 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $167.05 | 2019 | |
| Sunovion Pharmaceuticals INC. | $155.21 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $135.60 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $135.16 | 2024 | Voquezna |
| Novartis Pharmaceuticals Corporation | $128.64 | 2019-2023 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafat Choudhry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.